tyrosine and lomustine

tyrosine has been researched along with lomustine in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	2 (66.67)	2.80

Authors

Authors	Studies
Bauer, EK; Ceccon, G; Dunkl, V; Fink, GR; Galldiks, N; Henriksen, OM; Langen, KJ; Law, I; Lohmann, P; Muhic, A; Poulsen, HS; Schmidt, M; Shah, NJ; Steger, J; Stoffels, G; Tscherpel, C	1
Bauer, EK; Baues, C; Ceccon, G; Celik, E; Fink, GR; Galldiks, N; Gielen, GH; Herrlinger, U; Kabbasch, C; Langen, KJ; Lohmann, P; Marnitz, S; Schäfer, N; Schaub, C; Stoffels, G; Tscherpel, C; Weller, J; Werner, JM	1
Bauer, EK; Ceccon, GS; Fink, GR; Galldiks, N; Goldbrunner, R; Kabbasch, C; Langen, KJ; Lohmann, P; Stoffels, G; Tscherpel, C; Werner, JM; Wollring, MM	1

Trials

1 trial(s) available for tyrosine and lomustine

Article	Year
Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine. European journal of nuclear medicine and molecular imaging, 2018, Volume: 45, Issue:13 Topics: Adult; Aged; Bevacizumab; Disease Progression; Drug Interactions; Female; Glioblastoma; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Positron-Emission Tomography; Survival Analysis; Treatment Outcome; Tyrosine	2018

Article

Year

Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine.

European journal of nuclear medicine and molecular imaging, 2018, Volume: 45, Issue:13

Topics: Adult; Aged; Bevacizumab; Disease Progression; Drug Interactions; Female; Glioblastoma; Humans; Lomustine; Magnetic Resonance Imaging; Male; Middle Aged; Positron-Emission Tomography; Survival Analysis; Treatment Outcome; Tyrosine

2018

Other Studies

2 other study(ies) available for tyrosine and lomustine

Article	Year
Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 07-01, Volume: 27, Issue:13 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Disease Progression; Female; Glioblastoma; Humans; Lomustine; Male; Middle Aged; Positron-Emission Tomography; Retrospective Studies; Temozolomide; Tyrosine	2021
Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET. Neuro-oncology, 2023, 05-04, Volume: 25, Issue:5 Topics: Adult; Brain Neoplasms; Glioma; Humans; Lomustine; Magnetic Resonance Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tyrosine	2023

Article

Year

Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 07-01, Volume: 27, Issue:13

Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Disease Progression; Female; Glioblastoma; Humans; Lomustine; Male; Middle Aged; Positron-Emission Tomography; Retrospective Studies; Temozolomide; Tyrosine

2021

Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET.

Neuro-oncology, 2023, 05-04, Volume: 25, Issue:5

Topics: Adult; Brain Neoplasms; Glioma; Humans; Lomustine; Magnetic Resonance Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Tyrosine

2023